The economics of parallel trade

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 293-304

  Danzon, Patricia M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; LAW; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

COMMERCE; COSTS AND COST ANALYSIS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; PHARMACEUTICAL PREPARATIONS;

EID: 0031914249     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00004     Document Type: Review

References (17)

1. Remit Consultants. Single market review 1996: impact on manufacturing pharmaceutical products. London: Remit Consultants, 1996
2. MacArthur D. Bangemann round table: no break in EU pricing impasse. Pharma Pricing Rev 1997; 2 (1): 1-6
3. Danzon PM. Trade and price differentials for pharmaceuticals: policy options. London: Office of Health Economics (OHE), 1997
4. Pharmaceutical Research and Manufacturers of America (PhRMA). Industry profile. Washington, DC: PhRMA, 1997
5. DiMasi JA, Hansen RW, Grabowski HG, et al. The cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42
6. US Government Office of Technology Assessment (OTA). Pharmaceutical R&D: costs, risks and rewards. Washington, DC: OTA, 1993
7. Danzon PM. The effects of price regulation for pharmaceuticals: national vs. global interests. Washington, DC: The American Enterprise Institute Press, 1997
8. Grabowski HG, Vernon JM. 1992. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Act. J Law Econ 1992; 35: 331-50
9. Clarkson KW. The effects of research and promotion on rates of return. In: Helms R, editor. Competitive strategies in the pharmaceutical industry. Washington, DC: The American Enterprise Institute Press, 1996
10. Ramsey FP. A contribution to the theory of taxation. Econ J 1927; 37: 47-61
11. Baumol WJ, Bradford DF. Optimal departures from marginal cost pricing. Am Econ Rev 1970; 60: 265-83
12. Laffont J-J, Tirole J. 1993. A theory of incentives in procurement and regulation. Cambridge: MIT Press, 1993
13. Brittan L. Brittan speech on pharmaceutical pricing [press release]. Brussels: European Commission. 1992 Dec 2
14. Danzon PM, Percy A. The effects of price regulation on productivity in pharmaceuticals: studies on income and wealth. Proceedings of a Conference on Income and Wealth: 1996 Mar: Washington, DC. New York: National Bureau of Economic Research (NBER). In press
15. Thomas LG. Industrial policy and international competitiveness in the pharmaceutical industry. In: Helms RB, editor. Competitive strategies in the pharmaceutical industry. Washington, DC: The American Enterprise Institute Press, 1996
16. Varian H. 1989. Price discrimination. In: Schmalensee R, Willig R, editors. Handbook of industrial organization. Amsterdam: North Holland, 1989
17. Danzon PM. Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int J Econ Bus 1997; 4 (3): 303-23